• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助动脉内化疗和放疗联合口服 S-1 治疗 III 期和 IV 期口腔癌的临床和组织病理学效果。

Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer.

机构信息

Department of Oral Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Department of Oral Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan.

出版信息

Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Sep;134(3):347-353. doi: 10.1016/j.oooo.2022.04.042. Epub 2022 Apr 21.

DOI:10.1016/j.oooo.2022.04.042
PMID:35869018
Abstract

OBJECTIVE

The aim of this study was to examine the clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy (IACRT) using cisplatin in combination with oral S-1 (tegafur/gimeracil/oteracil potassium) on stage III and IV oral squamous cell carcinoma.

STUDY DESIGN

Thirty patients received infusions of superselective intra-arterial cisplatin 60 mg/m by the Seldinger method and conventional external beam radiotherapy (total 40 Gy) combined with oral S-1 on the day of irradiation. Curative surgery and neck dissection were performed 4 to 6 weeks after IACRT. The clinical response of the primary lesion was evaluated approximately 4 weeks after IACRT. The surgically resected specimens were examined for histologic features according to the grading system for histologic evaluation and for residual tumor grade (RGrades).

RESULTS

Histopathologic evaluation of the therapeutic effect was grade 2 in 10 patients and grade 3 in 16 patients. According to the distribution of RGrades, the remaining tumor cells were mostly in the central area of the primary lesion, as seen in 24 patients.

CONCLUSIONS

These findings indicate that neoadjuvant IACRT with cisplatin and oral S-1 was an effective treatment, suggesting the possibility of reducing the extent of curative surgery based on RGrades.

摘要

目的

本研究旨在探讨新辅助经动脉顺铂联合口服 S-1(替加氟/吉美嘧啶/奥替拉西钾)化疗放疗对 III 期和 IV 期口腔鳞状细胞癌的临床和组织病理学影响。

研究设计

30 例患者采用 Seldinger 法经超选择性动脉内输注顺铂 60mg/m2,并在照射日给予常规外照射放疗(总剂量 40Gy)联合口服 S-1。IACRT 后 4 至 6 周进行根治性手术和颈淋巴结清扫术。IACRT 后约 4 周评估原发病灶的临床反应。根据组织学评价分级系统和残留肿瘤分级(RGrades)对手术切除标本进行组织学特征检查。

结果

10 例患者的组织病理学评价为 2 级,16 例患者为 3 级。根据 RGrades 的分布,24 例患者的原发肿瘤中央区域仍可见较多残余肿瘤细胞。

结论

这些发现表明,顺铂联合口服 S-1 的新辅助经动脉化疗放疗是一种有效的治疗方法,根据 RGrades 有可能减少根治性手术的范围。

相似文献

1
Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer.新辅助动脉内化疗和放疗联合口服 S-1 治疗 III 期和 IV 期口腔癌的临床和组织病理学效果。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Sep;134(3):347-353. doi: 10.1016/j.oooo.2022.04.042. Epub 2022 Apr 21.
2
Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.采用超选择性经颞浅动脉和枕动脉动脉内灌注热化疗治疗伴有颈 N3 转移的口腔癌。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e639-45. doi: 10.1016/j.ijrobp.2012.02.057. Epub 2012 Apr 28.
3
Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases.逆行超选择性动脉内化疗联合每日同步放疗治疗Ⅲ期和Ⅳ期口腔癌:112例治疗结果分析
Radiother Oncol. 2014 May;111(2):306-10. doi: 10.1016/j.radonc.2014.03.005. Epub 2014 Apr 17.
4
Superselective arterial infusion chemotherapy for squamous cell carcinomas of the oral cavity: histopathologic effects on metastatic neck lymph nodes.口腔鳞状细胞癌的超选择性动脉灌注化疗:对颈部转移性淋巴结的组织病理学影响
Eur Arch Otorhinolaryngol. 2007 Mar;264(3):269-75. doi: 10.1007/s00405-006-0183-y. Epub 2006 Oct 24.
5
Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas.同期逆行超选择性动脉内灌注化疗联合西妥昔单抗治疗同步多发口腔鳞癌的疗效。
Radiat Oncol. 2023 May 26;18(1):90. doi: 10.1186/s13014-023-02282-9.
6
Thermochemoradiotherapy Using Superselective Intra-arterial Infusion for Patients With Oral Cancer With Cervical Lymph Node Metastases.超选择性动脉内灌注热化疗放疗用于治疗伴有颈部淋巴结转移的口腔癌患者
Anticancer Res. 2019 Mar;39(3):1365-1373. doi: 10.21873/anticanres.13250.
7
Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results.术前同步放化疗联合根治性手术治疗晚期口腔鳞状细胞癌:长期结果分析
Oral Oncol. 1999 Nov;35(6):597-606. doi: 10.1016/s1368-8375(99)00044-5.
8
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.新辅助化疗后序贯同步放化疗治疗局部晚期鼻咽癌。
Chin J Cancer. 2010 May;29(5):551-5. doi: 10.5732/cjc.009.10518.
9
Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III-IVB tongue cancer.III-IVB期舌癌交替放化疗后质子束治疗增敏联合动脉内灌注化疗的治疗结果
J Cancer Res Clin Oncol. 2016 Mar;142(3):659-67. doi: 10.1007/s00432-015-2069-0. Epub 2015 Oct 31.
10
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].[口服S-1后序贯多西他赛经超选择性动脉内灌注的联合化疗方案治疗口腔鳞状细胞癌患者的疗效评估]
Gan To Kagaku Ryoho. 2011 May;38(5):777-81.

引用本文的文献

1
Cisplatin intra-arterial chemotherapy for recurrent maxillary gingival cancer and metastatic lymph nodes without radiation or surgery: A case report.顺铂动脉内化疗治疗复发性上颌牙龈癌及转移性淋巴结,无需放疗或手术:病例报告
Radiol Case Rep. 2024 Nov 6;20(1):560-565. doi: 10.1016/j.radcr.2024.10.081. eCollection 2025 Jan.
2
Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.经动脉化疗放疗联合手术治疗口腔癌患者的免疫组织化学评估。
Med Mol Morphol. 2023 Dec;56(4):288-296. doi: 10.1007/s00795-023-00367-8. Epub 2023 Jul 29.